c-Myc and Sp1 Contribute to Proviral Latency by Recruiting Histone Deacetylase 1 to the Human Immunodeficiency Virus Type 1 Promoter

ABSTRACT Histone deacetylase (HDAC) inhibitors such as valproic acid (VPA) induce the expression of quiescent proviral human immunodeficiency virus type 1 (HIV-1) and may deplete proviral infection in vivo. To uncover novel molecular mechanisms that maintain HIV latency, we sought cellular mRNAs whose expression was diminished in resting CD4+ T cells of HIV-1-infected patients exposed to VPA. c-Myc was prominent among genes markedly downregulated upon exposure to VPA. c-Myc expression repressed HIV-1 expression in chronically infected cell lines. Chromatin immunoprecipitation (ChIP) assays revealed that c-Myc and HDAC1 are coordinately resident at the HIV-1 long terminal repeat (LTR) promoter and absent from the promoter after VPA treatment in concert with histone acetylation, RNA polymerase II recruitment, and LTR expression. Sequential ChIP assays demonstrated that c-Myc, Sp1, and HDAC1 coexist in the same DNA-protein complex at the HIV promoter. Short hairpin RNA inhibition of c-Myc reduces both c-Myc and HDAC1 occupancy, blocks c-Myc repression of Tat activation, and increases LTR expression. These results expand the understanding of mechanisms that recruit HDAC and maintain the latency of HIV-1, suggesting novel therapeutic approaches against latent proviral HIV infection.

[1]  J. Leonard,et al.  The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity , 1989, Journal of virology.

[2]  G. Inghirami,et al.  Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells. , 1990, Science.

[3]  J. Leonard,et al.  Variable role of the long terminal repeat Sp1-binding sites in human immunodeficiency virus replication in T lymphocytes , 1991, Journal of virology.

[4]  D. Margolis,et al.  Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. , 1992, Virology.

[5]  R. Pomerantz,et al.  Sodium butyrate stimulation of HIV-1 gene expression: a novel mechanism of induction independent of NF-kappa B. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[6]  C. Van Lint,et al.  The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.

[7]  E. Verdin,et al.  Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. , 1997, Genes & development.

[8]  F. Kashanchi,et al.  Rapid and sensitive detection of cell‐associated HIV‐1 in latently infected cell lines and in patient cells using sodium‐n‐butyrate induction and RT‐PCR , 1997, Journal of medical virology.

[9]  A. Fornace,et al.  Myc represses the growth arrest gene gadd45 , 1997, Oncogene.

[10]  Q. Zhan,et al.  Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA-damaging agents , 1998, Oncogene.

[11]  Kou-Juey Wu,et al.  Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. , 1999, Science.

[12]  K. Zeller,et al.  Function of the c-Myc oncogenic transcription factor. , 1999, Experimental cell research.

[13]  S. Salghetti,et al.  Destruction of Myc by ubiquitin‐mediated proteolysis: cancer‐associated and transforming mutations stabilize Myc , 1999, The EMBO journal.

[14]  C. Van Lint Role of chromatin in HIV-1 transcriptional regulation. , 2000, Advances in pharmacology.

[15]  J. Massagué,et al.  Repression of p15INK4b expression by Myc through association with Miz-1 , 2001, Nature Cell Biology.

[16]  T. Taira,et al.  RECRUITMENT OF A TRANSCRIPTIONAL COREPRESSOR COMPLEX TO c-Myc BY MM-1, A c-Myc-BINDING PROTEIN* , 2001 .

[17]  Yudong D. He,et al.  Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer , 2001, Nature Biotechnology.

[18]  L. Penn,et al.  Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor. , 2001, Journal of cell science.

[19]  Anne F. Buckley,et al.  Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc–dependent pathway , 2001, Nature Immunology.

[20]  A. Gartel,et al.  Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Penn,et al.  Mechanism for the transcriptional repression by c-Myc on PDGF (β)-receptor , 2001 .

[22]  F. Kashanchi,et al.  Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals , 2002, BMC Biochemistry.

[23]  W. Löscher Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. , 2002, CNS drugs.

[24]  C. Van Lint,et al.  Diversity of acetylation targets and roles in transcriptional regulation: the human immunodeficiency virus type 1 promoter as a model system. , 2002, Biochemical pharmacology.

[25]  D. Margolis,et al.  Counterregulation of Chromatin Deacetylation and Histone Deacetylase Occupancy at the Integrated Promoter of Human Immunodeficiency Virus Type 1 (HIV-1) by the HIV-1 Repressor YY1 and HIV-1 Activator Tat , 2002, Molecular and Cellular Biology.

[26]  Ben Berkhout,et al.  Synergistic Activation of Human Immunodeficiency Virus Type 1 Promoter Activity by NF-κB and Inhibitors of Deacetylases: Potential Perspectives for the Development of Therapeutic Strategies , 2002, Journal of Virology.

[27]  W. Löscher Basic Pharmacology of Valproate , 2002 .

[28]  D. Margolis,et al.  Targeted Derepression of the Human Immunodeficiency Virus Type 1 Long Terminal Repeat by Pyrrole-Imidazole Polyamides , 2002, Journal of Virology.

[29]  M. Giacca,et al.  Regulation of HIV‐1 gene expression by histone acetylation and factor recruitment at the LTR promoter , 2003, The EMBO journal.

[30]  Sharmistha Pal,et al.  mSin3A/Histone Deacetylase 2- and PRMT5-Containing Brg1 Complex Is Involved in Transcriptional Repression of the Myc Target Gene cad , 2003, Molecular and Cellular Biology.

[31]  M. Szyf,et al.  Valproate Induces Replication-independent Active DNA Demethylation* , 2003, Journal of Biological Chemistry.

[32]  R. Siliciano,et al.  Resting CD4+ T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes , 2004, Journal of Virology.

[33]  R. Siliciano,et al.  The multifactorial nature of HIV-1 latency. , 2004, Trends in molecular medicine.

[34]  R. Kuefer,et al.  Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer , 2004, British Journal of Cancer.

[35]  L. Penn,et al.  Repression of the human immunodeficiency virus type‐1 long terminal repeat by the c‐Myc oncoprotein , 2004, Journal of cellular biochemistry.

[36]  R. Bosch,et al.  Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression , 2004, AIDS.

[37]  R. Bosch,et al.  Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. , 2004, The Journal of infectious diseases.

[38]  P. Atadja,et al.  Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 , 2004, Clinical Cancer Research.

[39]  P. Iversen,et al.  In vivo Bioavailability and Pharmacokinetics of a c-MYC Antisense Phosphorodiamidate Morpholino Oligomer, AVI-4126, in Solid Tumors , 2005, Clinical Cancer Research.

[40]  A. Marcello Latency: the hidden HIV-1 challenge , 2006, Retrovirology.

[41]  T. Kouzarides,et al.  Myc represses transcription through recruitment of DNA methyltransferase corepressor , 2005, The EMBO journal.

[42]  Cheryl Jennings,et al.  Depletion of latent HIV-1 infection in vivo: a proof-of-concept study , 2005, The Lancet.

[43]  Ernest Martinez,et al.  Dual Regulation of c-Myc by p300 via Acetylation-Dependent Control of Myc Protein Turnover and Coactivation of Myc-Induced Transcription , 2005, Molecular and Cellular Biology.

[44]  S. Voelter-Mahlknecht,et al.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. , 2005, International journal of molecular medicine.

[45]  C. Lau,et al.  Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC , 2005, Molecular Cancer Therapeutics.

[46]  D. Grayson,et al.  Histone deacetylase inhibitors decrease reelin promoter methylation in vitro , 2005, Journal of neurochemistry.

[47]  C. Van Lint,et al.  COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells , 2005, Nucleic acids research.

[48]  P. Munster,et al.  Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. , 2005, Cancer research.

[49]  T. Okamoto,et al.  Transcriptional Repression of Human Immunodeficiency Virus Type 1 by AP-4* , 2006, Journal of Biological Chemistry.

[50]  A. Gartel A new mode of transcriptional repression by c-myc: methylation , 2006, Oncogene.

[51]  E. Verdin,et al.  NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation , 2006, The EMBO journal.

[52]  Richard D Moore,et al.  Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. , 2007, The Journal of infectious diseases.